# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) (NASDAQ:ENTO) ("Entero" or the "Company"), a l...
First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharm...
HC Wainwright & Co. analyst Yi Chen reinstates First Wave BioPharma (NASDAQ:FWBI) with a Neutral.
Roth MKM analyst Jonathan Aschoff maintains First Wave BioPharma (NASDAQ:FWBI) with a Buy and lowers the price target from $...
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarte...
First Wave BioPharma acquires ImmunogenX, focusing on advancing GI pipeline. James Sapirstein remains Chairman & CEO, with ...